Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001993
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine AZT to Symptomatic HIV-1 Infected Patients With or 200 to or 500 CD4 Cellsmm3
Sponsor:
G D Searle
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine AZT to Symptomatic HIV-1 Infected Patients With or 200 to or 500 CD4 Cellsmm3
Status:
COMPLETED
Status Verified Date:
1992-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to determine the preliminary efficacy and tolerability of combining a selected dose of SC-48334 with low-dose AZT in the treatment of symptomatic HIV patients with 200 to 500 CD4 cellsmm3
The secondary objective is to determine the pharmacokinetics and bioavailability of both SC-48334 and AZT when administered together in symptomatic HIV patients with 200 - 500 CD4 cellsmm3
The secondary objective is to determine the pharmacokinetics and bioavailability of both SC-48334 and AZT when administered together in symptomatic HIV patients with 200 - 500 CD4 cellsmm3
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NS8-90-02-004 | None | None | None |